Natural history of t(11;14) multiple myeloma

A. Lakshman, M. Alhaj Moustafa, S Vincent Rajkumar, Angela Dispenzieri, Morie Gertz, F. K. Buadi, Martha Lacy, David M Dingli, A. L. Fonder, S. R. Hayman, M. A. Hobbs, Wilson Gonsalves, Y. L. Hwa, Prashant Kapoor, N. Leung, R. S. Go, Yi Lin, Taxiarchis Kourelis, J. A. Lust, Stephen J RussellS. R. Zeldenrust, R. A. Kyle, Shaji K Kumar

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalLeukemia
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Lakshman, A., Alhaj Moustafa, M., Rajkumar, S. V., Dispenzieri, A., Gertz, M., Buadi, F. K., Lacy, M., Dingli, D. M., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W., Hwa, Y. L., Kapoor, P., Leung, N., Go, R. S., Lin, Y., Kourelis, T., Lust, J. A., ... Kumar, S. K. (2018). Natural history of t(11;14) multiple myeloma. Leukemia, 32(1), 131-138. https://doi.org/10.1038/leu.2017.204